drugset / Trial / NCT04557397

Fruquintinib CYP3A Inhibitor and Inducer Study

NCT04557397

Phase 1 Completed 28 enrolled Hutchison Medipharma Limited Covance · collab
Non-randomizedCrossoverOpen-labelBasic science

Summary

A study to assess the effect of itraconazole, a strong CYP3A inhibitor, and the effect of rifampin, a strong CYP3A inducer, on the pharmacokinetics of fruquintinib in healthy subjects.

Timeline

Start
2020-09-02
Primary completion
2020-10-18
Completion
2020-10-18

Drugs

EvaluationDrugModalityDoseRoute
Subject Fruquintinib Small molecule Oral
Subject Itraconazole Small molecule
Subject Rifampin Small molecule

Indications

No indication recorded.